Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Observational Study to Evaluate the Safety of Levemir® in Diabetes
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 51170
- Registration Number
- NCT00659295
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Crawley, United Kingdom
Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2018-01-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 57610
- Registration Number
- NCT00659282
- Locations
- 🇸🇦
Novo Nordisk Investigational Site, Riyadh, Saudi Arabia
Observational Study in Type 2 Diabetes Treated by an Intensive Insulin Treatment (ICT) Containing Once Daily Levemir® (Insulin Detemir)
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2016-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2289
- Registration Number
- NCT00657930
Observational Study of Type 2 Diabetes Patients Failing on Oral Anti-diabetic Agents Initiated on Levemir® or Insulatard®
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 699
- Registration Number
- NCT00658099
- Locations
- 🇷🇴
Novo Nordisk Investigational Site, Bucharest, Romania
Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3495
- Registration Number
- NCT00657319
- Locations
- 🇭🇺
Novo Nordisk Investigational Site, Budapest, Hungary
Evaluation of Levemir® for the Treatment of Type 1 and 2 Diabetes
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3637
- Registration Number
- NCT00655044
- Locations
- 🇷🇺
Novo Nordisk Investigational Site, Moscow, Russian Federation
Observational Study of Safety and Tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the Treatment of Type 1 and Type 2 Diabetes Mellitus
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2286
- Registration Number
- NCT00655200
Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 244
- Registration Number
- NCT00634842
- Locations
- 🇵🇷
Novo Nordisk Investigational Site, Trujillo Alto, Puerto Rico
Effect of Biphasic Insulin Aspart 50 on Blood Glucose Control in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-03-03
- Last Posted Date
- 2014-10-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 441
- Registration Number
- NCT00627445
Efficacy and Safety of Biphasic Insulin Aspart 30 With Metformin in Type 2 Diabetes
Phase 4
Completed
- Conditions
- First Posted Date
- 2008-02-27
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 140
- Registration Number
- NCT00624364
- Locations
- 🇿🇦
Novo Nordisk Investigational Site, Richards Bay, South Africa
© Copyright 2024. All Rights Reserved by MedPath